Abstract: NADPH oxidases have recently been shown to contribute to the pathogenesis of hypertension. The development of specific inhibitors of these enzymes has focused attention on their potential therapeutic use in hypertensive disease. Two of the most specific inhibitors, gp91ds-tat and apocynin, have been shown to decrease blood pressure in animal models of hypertension. Other inhibitors, including diphenylene iodonium, aminoethyl benzenesulfono fluoride, S17834, PR39, protein kinase C inhibitors, and VAS2870, have shown promise in vitro, but their in vivo specificity, pharmacokinetics, and effectiveness in hypertension remains to be determined. Of importance, the currently available antihypertensive agents angiotensinconverting enyzme inhibitors and angiotensin receptor blockers also effectively inhibit NADPH oxidase activation. Similarly, the cholesterol-lowering agents, statins, have been shown to attenuate NADPH oxidase activation. Although, antioxidants act to scavenge the reactive oxygen species produced by these enzymes, their effectiveness is limited. Targeting NADPH homologues may have a distinct advantage over current therapies because it would specifically prevent the pathophysiological formation of reactive oxygen species that contributes to hypertension.
R
eactive oxygen species (ROS) are generally small molecules derived from oxygen that are able to modify cellular functions by reacting with macromolecules such as DNA, proteins, and lipids. In the vasculature, ROS family members superoxide and hydrogen peroxide play important roles as signaling molecules to regulate extracellular matrix dynamics, inflammation, cell proliferation, migration, and differentiation, as well as vessel contraction and relaxation. When ROS production in cells becomes altered so that pro-oxidant generating systems exhaust the capacity of antioxidant systems, oxidative stress ensues. This excess superoxide and hydrogen peroxide causes malignant signaling in the vasculature, which can lead to various cardiovascular complications. Recent studies in numerous animal models have established a strong link between ROS and the pathophysiological progression of hypertension.
ROS have been shown to promote hypertension by causing endothelial dysfunction, altered contractility, and vascular remodeling, which are common characteristics associated with the disease. Studies indicate that altered superoxide production decreases nitric oxide (NO) bioavailability by scavenging the compound and creating highly reactive peroxynitrite. 1 Peroxynitrite is then able to oxidize the NO synthase (NOS) cofactor tetrahydrobiopterin, which causes NOS uncoupling and initiates endothelial dysfunction. 2 Altered NO bioavailability caused by endothelial dysfunction then leads to impaired vasodilation. 2 This loss in vasodilation can be further compounded by increased vasoconstriction induced by excess superoxide. 3, 4 Both hydrogen peroxide and superoxide can regulate vessel tone, although hydrogen peroxide can also act as an vasodilator in some vascular beds. 5 These changes can contribute to hypertension, and prolonged exposure to these conditions can activate the compensatory vascular remodeling associated with hypertension. Vascular remodeling is a dynamic process that involves changes in cellular proliferation, apoptosis, migration, and extracellular matrix dynamics. 6, 7 Importantly, increased ROS production in hypertension directly affects many of these processes, 8 leading to vascular smooth muscle cell (VSMC) hypertrophy in large vessels and increased hyperplasia of VSMCs from smaller resistance vessels. 9, 10 Superoxide induces proliferation of VSMCs, and both hydrogen peroxide and superoxide mediate hypertrophy of VSMCs. 10, 11 Both prohypertensive agents such as angiotensin II (Ang II) and the increase in cyclic stretch that results from elevated blood pressure can directly increase ROS production and induce vascular hypertrophy. [12] [13] [14] Thus, both molecules are thought to play pivotal roles in compensatory vascular remodeling, and together with their other effects on the vessel wall, kidney, and brain, contribute to the development of hypertension. 8, 15, 16 In a wide variety of animal models of hypertension, including Ang II or endothelin-1 (ET-1) infusion, renin angiotensinogen system transgenics, spontaneously hypertensive rats (SHR), and mineralocorticoid [deoxycorticosterone acetate (DOCA)-salt] models, ROS levels are elevated. 17 Importantly, dietary antioxidants such as vitamins E and C along with the superoxide dismutase (SOD) mimetic tempol improve blood pressure in both renin-angiotensin systemdependent and low renin and angiotensin animal models. 17 Such data suggest that ROS are critically important in many types of hypertension.
ROLE OF NADPH OXIDASES IN HYPERTENSION
In the vasculature, ROS can be produced by a variety of cellular systems such as xanthine oxidases, lipooxygenases, cyclooxygenases, mitochondria, NOS, peroxidases, NADPH oxidases, as well as other heme containing proteins. One clearly established source of ROS is the family of NADPH oxidases. NADPH oxidases are multisubunit, membraneassociated proteins that catalyze the 1 electron reduction of oxygen using NADPH as an electron donor. 18 The NADPH oxidase was first and most extensively studied in neutrophils, where it was found to have 2 membrane-bound subunits, gp91phox (Nox2) and p22phox, known collectively as cytochrome b558. 19 Cytoplasmic subunits of functional importance in the phagocytic oxidase are p40phox, p47phox, p67phox, and Rac. 20 In the vasculature, Nox2-based oxidases are found in endothelial cells, the adventitia, and resistance arteries. Novel Nox subunits Nox1, Nox4, and Nox5 are also expressed throughout the vasculature, but they have different modes of regulation and therefore presumably different susceptibility to pharmacological interventions. NADPH oxidases containing Nox1, Nox2, and Nox4 subunits require p22phox for functionality. Nox1 can be regulated by p47phox and p67phox, but it is more highly activated by their homologues Noxo1 and Noxa1. 21 Coexpression studies have clearly demonstrated that Nox4 does not require any known cytosolic subunits for functionality, 22 although this has not been specifically shown in VSMCs.
Recent studies have shown that NADPH oxidasedependent production of ROS may contribute to some of the pathological characteristics of hypertension. p22phox, which is a common component of Nox1-, Nox2-, and Nox4-containing oxidases, is strongly associated with hypertension and vascular remodeling. Numerous studies in various rat models of hypertension, including SHR, mineralocorticoid DOCA salt, and Ang II-infused models, confirm an increase in NADPH oxidase activity and p22phox subunit expression in the vessel wall and kidney of hypertensive animals. [23] [24] [25] [26] [27] A contributory role for NADPH oxidases in hypertension has been established using genetically modified mice. In transgenic mice, overexpression of p22phox in VSMCs potentiates Ang II-induced aortic hypertrophy and hypertension. 28 Mice that lack Nox1 have a blunted pressor response to Ang II and increased vasodilation in response to acetylcholine. 29 Conversely, in animals that overexpress Nox1, Ang II infusion potentiates hypertension and aortic vascular hypertrophy is exacerbated. 30 These studies suggest that the increase in ROS production upon Ang II stimulation can partly be attributed to Nox1. Thus, Nox1 may play an important role in Ang IIinduced hypertension. In contrast, gp91phox has been implicated in renal artery clipping (2K1C) and DOCA salt models of hypertension. gp91phox knockout mice have lower blood pressure than their wild-type littermates, 31, 32 but they exhibit the same response to Ang II infusion. 33 Finally, p47phox knockout mice show a decreased pressor response to Ang II stimulation. 34 Taken together, this genetic evidence clearly supports a causative role of NADPH oxidases in hypertension, and it strongly suggests that inhibitors of these oxidases may be promising antihypertensive agents. Below we consider briefly the currently available NADPH oxidase inhibitors and clinically useful pharmacological interventions that target these pathways and discuss their specificity and efficacy.
NADPH OXIDASE PEPTIDE INHIBITORS gp91ds-tat
The creation and discovery of therapeutic compounds that can inhibit NADPH oxidase activity is an active area of investigation. One of the most specific and efficacious inhibitors so far developed is gp91ds-tat, created by Pagano and colleagues.
35 gp91ds-tat is a chimeric 18-amino acid peptide that has been shown to interfere with NADPH oxidase assembly and activation ( Figure 1 ). Nine of its amino acids mimic a region of gp91phox that interacts with p47phox. In cell-free systems, this docking sequence (ds) is then able to bind to p47phox and inhibit subunit assembly, 35, 36 thus blocking activation. The next 9 amino acids correspond to a specific sequence in the HIV viral coat, which allows the peptide to be internalized by cells. 35 In vitro assays indicate that gp91ds-tat inhibits the interaction between p47phox and gp91phox and begins to significantly decrease oxidase activity at 1 mM in intact human neutrophils. 35 In cell-free assays, gp91ds inhibits oxidase activity up to 80% 37 ; however, maximal inhibition occurs at 100 mM and is only 35% in intact human neutrophils. 35 gp91ds-tat has been shown to be specific in that it only inhibits superoxide production from the NADPH oxidases and not from xanthine oxidase, another common producer of superoxide in the vasculature. 35 gp91ds-tat does not act simply as a superoxide scavenger, because it does not inhibit the superoxide signal produced in vitro with potassium superoxide. 35 Although gp91ds-tat is designed to inhibit interactions between oxidases containing the gp91phox (Nox2) subunit, recent probes into sequence homology of Nox1 and Nox2 indicate that this peptide may be able to inhibit the assembly of Nox1 as well. 35 gp91ds-tat has also been shown to inhibit known Nox1-dependent responses. 38, 39 In experiments to evaluate the effects of gp91ds-tat on systolic blood pressure (SBP), researchers found that the peptide (at 10 mg/kg/d) could attenuate both superoxide production in the peripheral vasculature and hypertension in mice infused with Ang II.
35 gp91ds-tat also inhibits the dipsogenic response and increased blood pressure in response to Ang II treatment in WKY rats, possibly by inhibiting the neuronal chronotropic effects of Ang II. 40 Smooth muscle hypertrophy, which is a common characteristic of hypertension, was reduced by gene transfer of gp91ds into the adventitia. 41 gp91ds-tat has also been effective in attenuating some aspects of hypertension in salt-sensitive models. In the Recent studies have shown that NADPH oxidasedependent production of ROS may contribute to some of the pathological characteristics of hypertension.
Dahl salt-sensitive rat model, gp91ds-tat ameliorates endothelial dysfunction by reducing vascular superoxide and peroxynitrite formation, but it has no significant effect on blood pressure. 42 Although this inhibitor is experimentally useful in animals, gp91ds-tat can only be administered intravenously due to its limited oral bioavailability and thus has limited widespread clinical application in its present form. Another concern is the potential of this peptide to generate an immune response over long-term use. Furthermore, this peptide is unlikely to inhibit NADPH oxidases that use cytosolic subunits and protein structures that significantly differ from gp91phox (Nox2), such as Nox4 and Nox5, although these oxidases have not as yet been linked to hypertension. Unfortunately, our knowledge of the pharmacokinetics of gp91ds-tat is limited, and further classical pharmacological studies need to be completed in vivo.
PR-39
Another peptide-based inhibitor of NADPH oxidase activity is PR-39. Originally isolated from the pig intestine, PR-39 is a naturally occurring, 39-amino acid antibiotic peptide effective against Gram-negative bacteria.
43 PR39 interferes with oxidase activity by binding to the SH3 domain of p47phox and inhibiting oxidase assembly, much like gp91ds-tat (Figure 1) . 44 In cell-free assays with neutrophils, superoxide production was inhibited by PR-39 with an IC50 value of 1 mM. 44 Treatment of rats with this peptide (250 mg) has been proven successful in reducing ROS levels and exerting protective effects in ischemia and reperfusion. 45 However, PR-39 is fairly nonspecific due to its ability to bind many proteins that have SH3 domains and interact with membrane lipids. 46 In addition, it has limited bioavailablity due to its peptide form.
NADPH OXIDASE CHEMICAL AND SMALL MOLECULE INHIBITORS VAS2870
Small molecule screening by Vasopharm Biotech recently uncovered a novel and specific NADPH oxidase inhibitor. VAS2870 [3-bezyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo(4,5-d)pyrimidine] was discovered via a high-throughput screening assay specific for NADPH oxidase activity and further characterized by NMR and mass spectrometry. 47 VAS2870 has an IC50 of 10.6 mM in cell-free systems using neutrophil membrane and cytosol, and an IC50 of 2 mM in HL-60 cells. 47 In both VSMCs and endothelial cells, VAS2870 is able to inhibit ROS production in response to PDGF and oxLDL without affecting basal ROS production. 47, 48 VSMC migration and Src phosphorylation in response to PDGF stimulation were also inhibited by VAS2870, 47 responses previously attributed to Nox1. Because Nox4 has been shown to be responsible for basal ROS production and VAS2870 inhibits only agonist-induced ROS production in VSMCs, this suggests that VAS2870 may have some specificity even within the NADPH oxidase family, although screening its activity against other NADPH oxidases remains to be performed.
Although VAS2870 shows promise in vitro studies, it has not yet been tested in any animal models, so pharmacokinetics, bioavailabiliy, and efficacy have not been established. However, the ability of VAS2870 to inhibit PDGF-mediated VSMC migration makes it a promising inhibitor for cardiovascular diseases with a component of vascular remodeling, provided it is active in vivo and has access to the media of the vessel. VAS2870 has also been shown to inhibit endothelial ROS production in response to oxLDL, 48 which may make it a useful inhibitor of the endothelial dysfunction that accompanies hypertension. 
Apocynin
Apocynin (4-hydroxy-3methoxy-acetophenone), a methoxycatechol extracted from the Picroria kurroa plant, was originally discovered as a potent inhibitor of superoxide in activated neutrophils. 49 It has since been studied as a possible remedy for inflammation-mediated diseases, including asthma, arthritis, and cardiovascular diseases. Apocynin is a pro-drug that is oxidized by peroxidases in the cell and converted into more active metabolites that are more potent than apocynin itself. 50 Although the exact mechanism by which apocynin inhibits NADPH oxidase activity is unknown, it is thought to impede oxidase assembly by interfering with the binding of p47phox to gp91phox (Figure 1) . 51 Human cellular studies using neutrophils revealed that apocynin has an IC50 of 10 mM when cells are stimulated with opsonized zymosan A (OPZ) or PMA. 49 In vivo, apocynin exhibits a very low toxicity with a LD50 of 9 g/kg when orally administered to mice, and it does not interfere with the killing capacity of PMNs. 49 It has also been used effectively in human VSMCs to inhibit superoxide production. 52 Apocynin has shown promising application in animal studies of hypertension and other cardiovascular diseases. In the Dahl salt-sensitive rat, apocynin inhibits superoxide production in the renal medulla and decreases hypertension. 53 DOCA salt-induced increases in aortic and renal superoxide production and hypertension are also attenuated by apocynin treatment. 23, 54 In this model, apocynin inhibits flow-induced superoxide production in the thick ascending loop of Henle, which is thought to mediate inappropriate NaCl retention in salt-sensitive hypertension, 55 and prevents endothelial dysfunction. 56 Apocynin also prevents and reverses increases in SBP in dexamethasone-induced hypertension. 57 Furthermore, apocynin is effective in treating humoral forms of hypertension such as those induced by Ang II and aldosterone. In Ang II-infused mice, apocynin prevents increases in SBP, improves acetylcholine-mediated vasodilation, and inhibits increases in collagen deposition in mesenteric arteries. 58 Aldosteroneinfused animals exhibit decreases in p22phox mRNA expression, procollagen I mRNA expression, and NADPH oxidase activity in the aorta and smaller increases in SBP when treated with apocynin. 59 These studies suggest that apocynin is a promising potential treatment for hypertension; however, its utility in human hypertensive patients remains to be determined.
There are, however, potential drawbacks to the use of apocynin. One concern is the requirement that apocynin be converted to its active metabolite, which may result in lowered efficacy and a wide variety of IC50s across various tissue beds. In addition, recent studies suggest that the apocynin reduction in ROS production may not be completely specific to NADPH oxidase inhibition. Apocynin has been shown to inhibit thomboxane A 2 formation in pulmonary macrophages 60 and to induce glutathione synthesis in alveolar epithelial cells via AP-1 activation. 61 Although these results suggest nonspecific behaviors of apocynin, whether these events are downstream of NADPH oxidase inhibition has not been investigated. A more serious potential problem comes from studies showing that apocynin may actually increase oxidative stress under some conditions. Glutathione expression is decreased in response to apocynin treatment in alveolar epithelial cells, 51, 62 and apocynin activation by myeloperoxidase produces an apocynin free radical that is able to oxidize glutathione. 51 Glial cells treated with apocynin show a dosedependent increase in oxidative stress markers, including increases in oxidized glutathione. 62 Oxidative stress becomes apparent at concentrations as low as 30 mM, which is within commonly administered doses of 10 mM to 1 mM of apocynin. 62 In vascular fibroblasts, apocynin also increases superoxide production at 100 mM. 63 Unfortunately, apocynin must be administered at high doses for effectiveness. Clearly a more extensive investigation of the effects of high doses of apocynin on glutathione metabolism and end organ damage is warranted. S17834 S17834 [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one] is a synthetic polyphenol that was originally discovered as a possible regulator of adhesion molecule expression for the treatment of chronic venous insufficiency. 64 Recent studies suggest that S17834 may mediate these effects by inhibiting NADPH oxidase activity. In endothelial cells, S17834 decreases NADPH oxidase activity, VCAM expession, and leukocyte adhesion. 65, 66 In apo E-deficient mice, S17834 decreases atherosclerotic lesion area. 65 These experiments suggest that S17834 may have therapeutic use in hypertension and other cardiovascular diseases. S17834 can be administered orally and was found to be efficacious in animal models of chronic venous insufficiency and atherosclerosis at doses between 10 and 130 mg/kg/d. 64, 65 Glucuroconjugates of S17834 have been identified after oral administration to hamsters and rats, suggesting possible phase II metabolism. 64 In cellular studies, S17834 exhibits some specificity in that it does not scavenge superoxide and has no effect on xanthine oxidase activity. 65 Furthermore, it is not toxic at concentrations up to 50 mM, as assessed by lactate dehydrogenase assay. 65 The mechanism of action by which S17834 inhibits oxidase activity is unknown, and additional studies are needed in vitro and in vivo to assess its promise as a specific NADPH oxidase inhibitor.
DPI
Diphenylene iodonium (DPI) is a commonly used potent inhibitor of NADPH oxidase activity. DPI was originally RBX was developed for use in diabetes because PKC mediates many of the effects of hyperglycmeia, but its ability to inhibit NADPH oxidase activity may be a beneficial side effect that will lead to its use in hypertension.
identified as a inhibitor of gluconeogenesis via inhibition of mitochondrial substrate oxidation. 67 Later research provided a role for DPI as an NADPH oxidase inhibitor. DPI is thought to attenuate oxidase activity by withdrawing an electron from the oxidase, causing adduct formation with FAD and inhibiting superoxide formation (Figure 1) . 68 DPI inhibits oxidase activity in cell free assays of human and pig neutrophils (10 mM) as well as in whole cells (20 mM). 68, 69 DPI has an estimated LD50 of 6 mg/kg in rats and 8 mg/kg in mice. 70 In rat and rabbit aorta and in rat carotid artery, DPI at 100 mM inhibits superoxide production in the DOCA and Ang II or ET-1 infused models of hypertension. 71, 72 However, the usefulness of DPI is limited due to the multiple cellular enzymes that are inhibited by this compound. DPI inhibits other flavin-containing enzymes such as NOS and cytochrome P450s. 19, 73, 74 In fact, the IC50 for inhibition of endothelium-mediated vasodilation is 0.18 mM, 75 far lower than for NADPH oxidase inhibtion. Due to the apparent effects on NOS, systemic use of DPI could have deleterious effects on hypertension by inhibiting NO production, which is critical for vasodilation. The hypoglycaemic effects of DPI also limit its clinical use.
AEBSF AEBSF (aminoethyl benzenesulfono fluoride), also known as Pefabloc, is another chemical inhibitor of the NADPH oxidase. In cell-free assays and in intact macrophages, AEBSF treatment inhibits NADPH oxidase activity by blocking the interaction between p47phox and membrane components of the oxidase (Figure 1) . 76 AEBSF is able to dose-dependently inhibit oxidative burst production in pulmonary macrophages and attenuates hypoxic pulmonary vasoconstriction. 77 It also attenuates proliferation of coronary microvascular endothelial cells associated with NADPH oxidase activity. 78 Only limited pharmacological data are available on this compound. In macrophages stimulated with PMA, an IC50 value of 1 mM was obtained. 76 However, AEBSF has other potential targets and is an irreversible serine protease inhibitor, 76 which makes it nonspecific and unsuitable for clinical use.
PKC INHIBITORS
Protein Kinase C (PKC) plays a pivitol role in NADPH oxidase activation, where it is responsible for p47phox phosphorylation (Figure 1) . Inhibition of PKC is thus a potential mechanism by which NADPH oxidase activity can be controlled. Inhibitors of PKC have shown great promise in animal and human conditions in which NADPH oxidase activity is elevated. In the 2K1C model of renal hypertension, inhibition of PKC by Calphostin C at 50 nM leads to superoxide inhibition. 79 In Ang II-infused rats, the PKC inhibitor chelerythrine (5 mg/kg/d) inhibits increased superoxide production and NADPH oxidase subunit upregulation. 80 In a human study with the selective PKCb inhibitor LY333531 (ruboxistaurin mesylate, RBX) at 32 mg/d, endothelial dysfunction was inhibited, possibly through inhibition of NADPH oxidase activity. 81 Despite these promising observations, it must be noted that PKC has many roles in the phosphorylation of multiple proteins that control cell permeability, gene transcription, and other cellular responses. Thus, inhibitors of PKC activity are not specific for NADPH oxidases and could have deleterious effects if used systemically. RBX is currently in clinical trials as a possible treatment for diabetic retinopathy, kidney, and blood vessel damage. [82] [83] [84] It has been found to be reasonably tolerated, although side effects such as dyspepsia and increased blood creatinine phosphokinase levels were reported. 84 RBX was developed for use in diabetes because PKC mediates many of the effects of hyperglycmeia, but its ability to inhibit NADPH oxidase activity may be a beneficial side effect that will lead to its use in hypertension.
Statins
The small GTPase Rac is an important component of the NADPH oxidase. HMG CoA reductase inhibitors or statins, a common class of drug used to control high cholesterol levels, have recently been shown to inhibit NADPH oxidase activity. They act by inhibiting geranylgeranylation of Rac, which prevents its translocation to the cell membrane ( Figure 1) . 85 In VSMCs, atorvastatin (10 mM) inhibits Ang II-induced and epidermal growth factor (EFG)-induced ROS production and downregulates Nox1 subunit expression. 85 In an in vivo model of hypertension, SHR, atorvastatin (50 mg/kg/d) decreases aortic superoxide production and NADPH oxidase subunit expression. 85 Atorvastatin also improves endothelial dysfunction and reduces aortic superoxide production and SBP in dexamethasone-infused rats. 86 In human studies, simvastin (20 mg/d) increases endothelial responsiveness (which is impaired by ROS) basally and in response to stimuli in individuals with elevated cholesterol levels. 87 Pravastatin (20 to 40 mg/d) alone improves blood pressure in patients with hypercholesterolemia and hypertension. 88 In patients already receiving antihypertensive therapy, pravastatin improves SBP in subjects with controlled and uncontrolled blood pressure. 89 Because statins inhibit small GTPases as well as cholesterol synthesis, they have a variety of potential therapeutic effects. Their ability to inhibit those NADPH oxidases that require Rac (Nox1 and Nox2) may thus underlie some of their beneficial effects, but statins cannot be used as specific NADPH oxidase inhibitors.
Angiotensin Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers
Ang II is a potent stimulus for NADPH oxidase activity in all cells of the vasculature, and for this agent more than any other, its hypertensive effects have been shown to be mediated in part by the resulting ROS generation. 29, 30 In addition, Ang II is a mediator of many other hypertensive stimuli. Thus, inhibitors of Ang II generation (ACE inhibitors) or Ang II receptor blockers (sartans) represent potential methods of blocking a major activator of NADPH oxidase-derived ROS (Figure 1 ). For example, in mononuclear leukocytes, the ACE inhibitors quinapril (10 mM) and captopril (10 mM) reduce ROS production in response to PMA stimulation. 90 Similarly, 91 In vivo, human therapeutic serum concentration levels of captopril and quinapril have been reported to be between 1 and 10 mM. 90 Mononuclear leukocytes from human patients who were orally administered 10 mg of quinapril show reduced PMA-stimulated ROS production. 90 In a small human study of patients with mild essential hypertension, the angiotensin receptor antagonist Losartan (50 mg) was able to correct endothelial dysfunction of resistance arteries. 92 Like PKC inhibitors and statins, these drugs have many beneficial cardiovascular effects because of the pleiotrophic actions of Ang II, but it should be kept in mind that NADPH oxidase inhibition may contribute to some of the improved cardiovascular endpoints.
Antioxidants
Although antioxidants do not act by directly inhibiting NADPH oxidase activity, they are able to scavenge and neutralize their products (Figure 1 ). Thus, they are able to inhibit the effects of NADPH activation. The superoxide dismutase mimetic tempol (tetramethylpiperidinol N-oxyl) is a currently used antioxidant in many animal studies. Tempol (1 mM) scavenges NADPH oxidase-derived ROS and attenuates hypertensive pathologies such as decreased NO signaling and endothelial dysfunction in salt-sensitive rats. 93 Its efficacy in human subjects has yet to be evaluated. Ebselen [2,-phenyl-1,2-benzisoselenazol-3(2H)-one, PZ 51, DR3305] is another commonly used antioxidant that acts by mimicking GSH peroxidases, reacting with peroxynitrite and inhibiting NADPH oxidases directly. 94 Numerous studies show a physiological efficacy of ebselen in inhibiting endothelial dysfunction and vascular remodeling, as well as decreasing blood pressure at varying concentrations. [95] [96] [97] Ebselen is currently in clinical trials for stroke prevention, and has shown limited efficacy. 98, 99 Finally, vitamins C and E are naturally occurring and widely administered antioxidants that have been disappointing in human use. In type I diabetes, vitamin C (1000 mg/d for 6 months) restored endothelial dysfunction. 100 In other studies of hypertension, long term administration of vitamin C (500 mg/d for 30 days) improved blood pressure. 101 However, in most clinical trials of the efficacy of vitamin supplementation for cardiovascular disease, dietary supplementation of vitamin E (400 IU) had no helpful or adverse effects on cardiovascular outcomes. 102 There are many reasons for the failure of these vitamin trials, as recently reviewed. 103, 104 Because of these negative results, many physicians have begun to question the oxidative hypothesis of vascular disease, but the overwhelming evidence from animal studies that ROS mediate hypertension argues against this interpretation. Rather, the failure of the vitamin trials suggests that treating the source of ROS, rather than attempting to scavenge them once they are formed, is a better strategy for the future.
CONCLUSIONS
Genetic studies have established that NADPH oxidases are a major source of deleterious superoxide production in hypertension. Inhibitors of these enzymes have been shown to attenuate hypertension and the resulting pathophysiological changes in animal models, and thus are promising potential human therapies. However, currently available inhibitors mainly target inhibition of oxidase assembly, and thus are mainly effective against Nox1 and Nox2. This has two major limitations. These drugs inhibit the neutrophil and macrophage antigen-mediated, Nox2-dependent respiratory burst, which could pose problems for immune function. Furthermore, ROS are important to normal vascular and immune health as well as disease. Thus, nondiscriminantly inhibiting NADPH oxidasederived ROS could lead to harmful side effects. We badly need additional information about the pharmacokinetics and specificity of most currently available NADPH oxidase inhibitors before they can be tested in hypertensive patients. On the basis of these considerations, however, new inhibitors of oxidase activity should be designed to be Nox isoform-specific so that specific pathologies can be targeted. Attention should also be given to developing alternate routes of administration, which might permit local actions of these drugs and avoid potentially compromising the immune response. With this in mind, the potential of anti-NADPH oxidase drugs as novel therapies for hypertension is indeed promising.
The failure of the vitamin trials suggests that treating the source of ROS, rather than attempting to scavenge them once they are formed, is a better strategy for the future.
